Efficacy and Safety of Chungkookjang on Improvement of Metabolic Syndrome

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01811511

Enrollment

120

Registered

2013-03-14

Start date

2013-03-31

Completion date

2014-02-28

Last updated

2015-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome

Brief summary

The investigators performed a 12-week, randomized, double-blind, placebo-controlled crossover human trial to evaluate the efficacy and safety of chungkookjang on improvement of metabolic syndrome. The investigators measured decrement of body fat parameters, including Body Fat Mass, Percent Body Fat, Fat Free Mass, Weight and BMI(body mass index), and monitored their blood pressure.

Interventions

DIETARY_SUPPLEMENTChungkookjang

DIETARY_SUPPLEMENTPlacebo

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

PREVENTION

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 29 Years

Healthy volunteers

Yes

Inclusion criteria

* Males and females 18-29 years old * BMI(body mass index) ≥ 23 kg/m2 or WC(Waist Circumference) ≥ 90(men), WC(Waist Circumference) ≥ 85(women) * Able to give informed consent

Exclusion criteria

* Allergic or hypersensitive to any of the ingredients in the test products * The diagnosis of type 1 and type 2 diabetes or fasting glucose ≥ 126mg/dL * Systolic pressure ≥ 160mmHg, diastolic pressure ≥ 100mmHg * History of reaction to any of the test products or of gastrointestinal diseases such as Crohn's disease or gastrointestinal surgery * History of alcohol or substance abuse * Participation in any other clinical trials within past 2 months * Laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study

Design outcomes

Primary

Measure	Time frame	Description
Change in Body Fat Mass	12 weeks	Body Fat Mass was measured in study visit 1(0 week) and visit 3(12 week).
Changes in Percent Body Fat	12 weeks	Percent Body Fat was measured in study visit 1(0 week) and visit 3(12 week).

Secondary

Measure	Time frame	Description
Change in Glucose	12 weeks	Glucose was measured in study visit 1(0 week) and visit 3(12 week).
Changes in Cholesterol	12 weeks	Cholesterol was measured in study visit 1(0 week) and visit 3(12 week).

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 22, 2026